A5040002151- Cardiac pacing and defibrillation studies
- Atrial Fibrillation Management and Outcomes
- Cardiac Arrhythmias and Treatments
- Cardiac electrophysiology and arrhythmias
- Cardiomyopathy and Myosin Studies
- Cardiac Valve Diseases and Treatments
- Mechanical Circulatory Support Devices
- Cardiovascular Effects of Exercise
- Cardiac Imaging and Diagnostics
- Platelet Disorders and Treatments
- Cardiac Arrest and Resuscitation
- Obstructive Sleep Apnea Research
- Cardiac Structural Anomalies and Repair
- Blood properties and coagulation
- Autoimmune Bullous Skin Diseases
- Cardiovascular and Diving-Related Complications
- Sarcoidosis and Beryllium Toxicity Research
- Acute Myocardial Infarction Research
- Viral Infections and Immunology Research
- Infective Endocarditis Diagnosis and Management
- Nanowire Synthesis and Applications
- ECG Monitoring and Analysis
- CAR-T cell therapy research
- Antiplatelet Therapy and Cardiovascular Diseases
- Pathogenesis and Treatment of Hiccups
Mercy Medical Center
2025
McMaster University
2023-2024
University of Toronto
2024
Centre for Addiction and Mental Health
2023
Rosalind Franklin University of Medicine and Science
2021-2023
Northwestern Medicine
2021-2023
Centegra Hospital McHenry
2022-2023
Patients with obstructive sleep apnea (OSA) have an increased risk for arrhythmias compared to patients without OSA. However, data quantifying the of inpatient complications in heart failure preserved ejection fraction (HFpEF) are lacking. We sought compare outcomes and occurrence HFpEF OSA, respectively. Furthermore, we prevalence nocturnal continuous positive airway pressure (CPAP) therapy. performed a retrospective study using National Inpatient Sample from 2016-2018 identify Propensity...
Bleeding tendency increases with concomitant use of ibrutinib and anticoagulants. Our patient presented shortness breath was found to have a nonmalignant hemorrhagic pericardial effusion. Ibrutinib resumed, percutaneous left atrial appendage occlusion performed as substitute for the chemical anticoagulation decrease drug-drug interaction. (Level Difficulty: Intermediate.).
Clinical trials of the messenger ribonucleic acid (mRNA)-1273 vaccine developed by Moderna proved excellent safety and efficacy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) prevention. However, Centers Disease Control Prevention (CDC) has been investigating cases myocarditis pericarditis reported in Vaccine Adverse Event Reporting System (VAERS) database. Currently, CDC is reporting rates 40.6 per million after second doses mRNA vaccines administered to males 30 years or...